Theralase Partners with University of Toledo in Cancer Research
18 Juni 2014 - 12:59PM
Access Wire
Toronto, Ontario / ACCESSWIRE / June 18, 2014 / Theralase Technologies Inc.
("Theralase") (TSXV: TLT)
(TLTFF: OTC Pink(R)) announced today that it has
executed an agreement with the University of Toledo to conduct
preclinical research into the safety and effectiveness of
Theralase's Photo Dynamic Compounds (PDCs) in the destruction of
bladder cancer in a rat model. The study is entitled,
"The use of novel Photo Dynamic
Therapy (PDT) in a rat bladder tumor model."
The first phase of this preclinical
study will be to optimize the effectiveness of various Theralase
PDCs in the destruction of rat bladder tumor cells (AY-27) using
various PDC concentrations and laser light doses.
The second phase will be to complete
two in
vivo rat tumor model studies. The
first set of experiments will examine PDC uptake and distribution
in rat bladder tumors. The second set of experiments will focus on
destroying rat bladder cancer safely and effectively through the
instillation of PDCs into rat bladders exhibiting cancerous tumours
and then light activating them.
The outcome of these experiments will
provide independent confirmation and optimization of the lead PDC
selected for bladder cancer destruction and prove the safety and
efficacy of the Theralase lead PDC in the destruction of bladder
cancer in a live animal model.
Dr. Arkady Mandel, Chief Scientific Officer at Theralase
Inc. stated, "I am interested in reviewing the results of an
independent confirmation and optimization of the safety and
efficacy of the Theralase PDC in destroying bladder cancer in an
orthotopic (occurring at the normal place) rat model. The
University of Toledo is a great choice for this research, as their
group is well known for expertise in the urological applications of
PDT. The results of this preclinical research will allow the
Company to progress to Good Manufacturing Practice (GMP)
manufacture of the lead PDC. We are delighted to have the
experience and knowledge of the University of Toledo on board to
execute this pivotal preclinical research, as they
will be instrumental in helping us prove the
destruction of rat bladder cancer with PDCs in 2014, preparing us
for clinical application in 2015."
Roger Dumoulin-White,
President and CEO of Theralase stated that, "Theralase is delighted
that we have executed a research agreement with the University of
Toledo. Completion of this work is pivotal for Theralase to
independently validate and optimize our research findings in the
PDT destruction of bladder cancer. Results of the University of
Toledo's work will determine the uptake and distribution of the
PDCs into bladder cancer tumors versus healthy bladder and the
amount of PDCs required to safely and effectively destroy bladder
cancer in a live animal model. This data will be instrumental in
helping to determine the proper amount of PDC required for human
application. I look forward to reporting on the results of this
exciting research later this year."
About Theralase Technologies Inc.
Theralase Technologies
Inc. ("Theralase")
(TSXV: TLT) (TLTFF: OTC
Pink(R)) designs, manufactures and markets patented,
superpulsed laser technology used in eliminating pain and
destroying cancer. Theralase technology is safe and effective in
eliminating pain, reducing inflammation and accelerating tissue
regeneration in numerous nerve, muscle and joint conditions.
Theralase is developing patented Photo Dynamic Compound (PDC)
technology that is able to target and destroy cancers, bacteria and
viruses when light activated.
Additional information is
available at www.theralase.com and
www.sedar.com
This press release contains
forward-looking statements, which reflect the Company's current
expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could
differ materially from those projected herein. The Company
disclaims any obligation to update these forward-looking
statements.
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchanges) accepts responsibility for
the adequacy or accuracy of this release.
For More Information:
Roger Dumoulin-White
President & CEO, Theralase Technologies
Inc.
1.866.THE.LASE (843.5273) x 225
416.699.LASE (5273) x 225
rwhite@theralase.com
www.theralase.com
Arkady Mandel
Chief Scientific Officer, Theralase Technologies Inc.
1.866.THE.LASE (843.5273) x 260
416.699.LASE (5273) x 260
amandel@theralase.com
www.theralase.com
SOURCE: Theralase Technologies Inc.
Theralase Technologies (TSXV:TLT)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Theralase Technologies (TSXV:TLT)
Historical Stock Chart
Von Jun 2023 bis Jun 2024